Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.
Clofibrate (a very effective lipid-lowering drug) may cause serious muscular damage in uraemic patients, even if used at appropriately low dose. Some authors have reported that D,L-Carnitine and Thiadenol can reduce lipid levels in non uraemic subjects, without adverse effects. In our study D,L-Carnitine and Thiadenol were administered for 3 months to respectively 21 and 15 patients on chronic haemodialysis with hypertriglyceridaemia. With D,L-Carnitine 52% of patients showed lower plasma triglycerides (TG) (-40.6%, p less than 0.002); after Thiadenol 66.6% of patients showed reduced plasma TG concentration (-42.9%, p less than 0.001). No dietary changes were recorded during the study. No major side effects nor biochemical changes were observed. D,L-Carnitine and Thiadenol appear to be less effective, but also less dangerous than Clofibrate in chronic uraemic patients.
D002331:Carnitine / Q000627:therapeutic use*; D002908:Chronic Disease; D002994:Clofibrate / Q000627:therapeutic use; D005233:Fatty Alcohols / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000150:complications / Q000188:drug therapy*; D050356:Lipid Metabolism; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications*
D005233:Fatty Alcohols; C004568:tiadenol; D002994:Clofibrate; D002331:Carnitine